ReviewCancers2021
Do Lipid-based Nanoparticles Hold Promise for Advancing the Clinical Translation of Anticancer Alkaloids?
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 33 citations in OpenAlex.
- Cancer Drug Delivery with Nanoparticles and Biomolecules: Stimuli-Responsive, Theranostic, and AI-Guided Approaches.Materials (Basel, Switzerland) · 2026Review
- Skin on Drugs: Psychotropic Compounds in Cutaneous Biology.International journal of molecular sciences · 2026Review
- Nanotechnology Meets Phytotherapy: A Comprehensive Review of Berberine in Cancer.Mini reviews in medicinal chemistry · 2026Review
- Lipid-based Nanoparticles as Drug Delivery System for Modern Therapeutics.Pharmaceutical nanotechnology · 2026Review
- Traversing the Valley of Death for nanotechnology-based natural products: strategies and insights from pharmaceutical stakeholders.Drug delivery and translational research · 2025Article
- Potential of Exosomes as Multifunctional Nanocarriers for Targeted Drug Delivery.Molecular biotechnology · 2025Review
- A Systematic Review of Advances in Plant-Based Phospholipid Liposomes in Breast Cancer Therapy: Characterization, Innovations, Clinical Applications, and Future Directions.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Enhanced Photodynamic Therapy Synergizing with Inhibition of Tumor Neutrophil Ferroptosis Boosts Anti-PD-1 Therapy of Gastric Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Recent advances in nanoformulation-based delivery for cancer immunotherapy.Nanomedicine (London, England) · 2024Review
- Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Nano-biotechnology in tumour and cancerous disease: A perspective review.Journal of cellular and molecular medicine · 2023Review
- New trends in diagnosing and treating ovarian cancer using nanotechnology.Frontiers in bioengineering and biotechnology · 2023Review
- A spotlight on alkaloid nanoformulations for the treatment of lung cancer.Frontiers in oncology · 2022Review
- Alkaloids as Photosensitisers for the Inactivation of Bacteria.Antibiotics (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the commercialization of morphine in 1826, numerous alkaloids have been isolated and exploited effectively for the betterment of mankind, including cancer treatment. However, the commercialization of alkaloids as anticancer agents has generally been limited by serious side effects due to their lack of specificity to cancer cells, indiscriminate tissue distribution and toxic formulation excipients. Lipid-based nanoparticles represent the most effective drug delivery system concerning clinical translation owing to their unique, appealing characteristics for drug delivery. To the extent of our knowledge, this is the first review to compile in vitro and in vivo evidence of encapsulating anticancer alkaloids in lipid-based nanoparticles. Alkaloids encapsulated in lipid-based nanoparticles have generally displayed enhanced in vitro cytotoxicity and an improved in vivo efficacy and toxicity profile than free alkaloids in various cancers. Encapsulated alkaloids also demonstrated the ability to overcome multidrug resistance in vitro and in vivo. These findings support the broad application of lipid-based nanoparticles to encapsulate anticancer alkaloids and facilitate their clinical translation. The review then discusses several limitations of the studies analyzed, particularly the discrepancies in reporting the pharmacokinetics, biodistribution and toxicity data. Finally, we conclude with examples of clinically successful encapsulated alkaloids that have received regulatory approval and are undergoing clinical evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.